3,037 reports of this reaction
2.8% of all UPADACITINIB reports
#5 most reported adverse reaction
RHEUMATOID ARTHRITIS is the #5 most commonly reported adverse reaction for UPADACITINIB, manufactured by AbbVie Inc.. There are 3,037 FDA adverse event reports linking UPADACITINIB to RHEUMATOID ARTHRITIS. This represents approximately 2.8% of all 110,317 adverse event reports for this drug.
UPADACITINIB has an overall safety score of 85 out of 100. Patients taking UPADACITINIB who experience rheumatoid arthritis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RHEUMATOID ARTHRITIS is a less commonly reported adverse event for UPADACITINIB, but still significant enough to appear in the safety profile.
In addition to rheumatoid arthritis, the following adverse reactions have been reported for UPADACITINIB:
The following drugs have also been linked to rheumatoid arthritis in FDA adverse event reports:
RHEUMATOID ARTHRITIS has been reported as an adverse event in 3,037 FDA reports for UPADACITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
RHEUMATOID ARTHRITIS accounts for approximately 2.8% of all adverse event reports for UPADACITINIB, making it a notable side effect.
If you experience rheumatoid arthritis while taking UPADACITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.